| Reconciliation Of Operating Profit Loss From Segments To Consolidated |
For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
|
Six months ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
|
(in thousands) |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Personnel |
|
$ |
12,001 |
|
|
$ |
9,401 |
|
|
$ |
23,366 |
|
|
$ |
17,164 |
|
Clinical trials |
|
|
9,070 |
|
|
|
5,313 |
|
|
|
17,581 |
|
|
|
9,735 |
|
Development services |
|
|
4,197 |
|
|
|
4,112 |
|
|
|
7,765 |
|
|
|
8,459 |
|
Manufacturing of preclinical and clinical supplies |
|
|
11,610 |
|
|
|
3,798 |
|
|
|
16,642 |
|
|
|
7,341 |
|
License of intellectual property |
|
|
— |
|
|
|
4 |
|
|
|
— |
|
|
|
1,515 |
|
Other research and development costs (1) |
|
|
760 |
|
|
|
799 |
|
|
|
1,302 |
|
|
|
1,167 |
|
General and administration expenses |
|
|
8,268 |
|
|
|
6,852 |
|
|
|
16,386 |
|
|
|
12,929 |
|
Interest income |
|
|
(1,410 |
) |
|
|
(2,677 |
) |
|
|
(2,897 |
) |
|
|
(5,661 |
) |
Interest expense |
|
|
571 |
|
|
|
— |
|
|
|
865 |
|
|
|
— |
|
Other expense |
|
|
61 |
|
|
|
|
|
|
61 |
|
|
|
|
Net loss |
|
$ |
45,128 |
|
|
$ |
27,602 |
|
|
$ |
81,071 |
|
|
$ |
52,649 |
|
(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.
|